Overview

Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus

Status:
Completed

Trial end date:
2008-12-22

Target enrollment:

Participant gender:

Summary

The objective of the study was to assess the long-term safety of daily doses of ospemifene 60 mg in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women without a uterus.

Phase:

Phase 3

Details

Lead Sponsor:

Shionogi

Collaborator:

QuatRx Pharmaceuticals

Treatments:

Tamoxifen